Hydroxychloroquine in Mild Graves' Orbitopathy
ConditionGraves Ophthalmopathy
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-75
SponsorNational Taiwan University Hospital
About this trial
This study is aimed to investigate the effect of hydroxychloroquine in patients with mild Graves' orbitopathy (GO).
Eligibility criteria
Qualifiers
Mild GO according European Group on Graves' orbitopathy (EUGOGO) guidelines diagnosed by endocrinologist and ophthalmologist.
No previous treatment of GO except for eyedrops
Euthyroidism (normalized free T4 and TSH) for at least 2 months. If radioactive iodine is used for hyperthyroidism, euthyroidism needs to be achieved for at least 6 months.
Disqualifiers
Moderate-to-sever or sight-threatening GO according to EUGOGO guidelines diagnosed by endocrinologist and ophthalmologist.
Pregnancy
Drug or alcohol abuse
Unable to comply with the study protocol
Trial design
Treatments tested in this trial
- Hydroxychloroquine
Treatment groups
108 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov